Lonza (SGX:O6Z) confirmed its full-year guidance after a strong third-quarter showing for its contract development and manufacturing organization (CDMO) business, according to a Thursday filing with the Singapore Exchange.

The Swiss contract drug manufacturer said its CDMO business remains on track for constant exchange rate (CER) sales growth of 20% to 21% and a core EBITDA margin of 30% to 31%.

Excluding the Vacaville contribution, organic CDMO sales growth is expected in the low teens.

The company also confirmed its outlook for the capsules & health ingredients segment, forecasting low- to mid-single-digit CER sales growth and a mid-twenties margin for the year.

Lonza said it expects no material financial impact from U.S. trade policy changes and continues to monitor biotech funding trends, noting stable utilization in its early-stage business.